Knockdown of stomatin-like protein 2 (STOML2) reduces the invasive ability of glioma cells through inhibition of the NF-κB/MMP-9 pathway

Journal of Pathology

Volumn 226, Issue 3, 2012, Pages 534-543

  Song, Libing ^a   Liu, Liping ^a   Wu, Zhiqiang ^b   Lin, Chuyong ^b   Dai, Ting ^b   Yu, Chunping ^a   Wang, Xi ^a,c   Wu, Jueheng ^b   Li, Mengfeng ^b   Li, Jun ^b  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY   (China)

Author keywords

glioma; invasiveness; NF B; prognosis; STOML2

Indexed keywords

GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; STOMATIN; STOMATIN LIKE PROTEIN 2; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER CELL CULTURE; CANCER PROGNOSIS; CELL INVASION; CELL MIGRATION; DOWN REGULATION; ENZYME INDUCTION; ENZYME INHIBITION; FEMALE; GENE REPRESSION; GENE SILENCING; GLIOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL TIME; TRANSCRIPTION INITIATION; UPREGULATION;

ADOLESCENT; ADULT; AGED; BLOOD PROTEINS; CELL LINE, TUMOR; CELL MOVEMENT; CHILD; CHILD, PRESCHOOL; DOWN-REGULATION; FEMALE; GENE KNOCKDOWN TECHNIQUES; GENE SILENCING; GLIOMA; HUMANS; INFANT; KAPLAN-MEIER ESTIMATE; MALE; MATRIX METALLOPROTEINASE 9; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NF-KAPPA B; PROGNOSIS; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION; UP-REGULATION; YOUNG ADULT;

EID: 84856034452     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.3008     Document Type: Article

References (39)

1. Taylor LP,. Diagnosis, treatment, and prognosis of glioma: five new things. Neurology 2010; 75: S28-S32.
2. Stupp R, Mason WP, van den Bent MJ, et al., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996. (Pubitemid 40349501)
3. Brada M, Stenning S, Gabe R, et al., Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. J Clin Oncol 2010; 28: 4601-4608.
4. Morris PG, Lassman AB,. Medical oncology: optimizing chemotherapy and radiotherapy for anaplastic glioma. Nature Rev Clin Oncol 2010; 7: 428-430.
5. Roesler R, Brunetto AT, Abujamra AL, et al., Current and emerging molecular targets in glioma. Expert Rev Anticancer Ther 2010; 10: 1735-1751.
6. Gabayan AJ, Green SB, Sanan A, et al., GliaSite brachytherapy for treatment of recurrent malignant gliomas: a retrospective multi-institutional analysis. Neurosurgery 2006; 58: 701-709.
7. Sciumè G, Santoni A, Bernardini G,. Chemokines and glioma: invasion and more. J Neuroimmunol 2010; 224: 8-12.
8. Butowski NA, Sneed PK, Chang SM,. Diagnosis and treatment of recurrent high-grade gliomas. J Clin Oncol 2006; 24: 1273-1280. (Pubitemid 46622030)
9. See SJ, Gilbert MR,. Anaplastic gliomas: diagnosis, prognosis, and management. J Clin Oncol 2004; 31: 618-634. (Pubitemid 39389013)
10. Green JB, Young JP,. Slipins: ancient origin, duplication and diversification of the stomatin protein family. BMC Evol Biol 2008; 8: 44-55.
11. Wang Y, Morrow JS,. Identification and characterization of human SLP-2, a novel homologue of stomatin present in erythrocytes and other tissues. J Biol Chem 2000; 275: 8062-8071. (Pubitemid 30159719)
12. 2+-relevant and differentiation associated genes down-regulated in esophageal squamous cell carcinoma using cDNA microarray. Oncogene 2004; 23: 1291-1299. (Pubitemid 38297184)
13. Zhang L, Ding F, Cao W, et al., Stomatin-like protein 2 is overexpressed in cancer and involved in regulating cell growth and cell adhesion in human esophageal squamous cell carcinoma. Clin Cancer Res 2006; 12: 1639-1646.
14. Wang Y, Cao W, Yu Z, et al., Downregulation of a mitochondria associated protein SLP-2 inhibits tumor cell motility, proliferation and enhances cell sensitivity to chemotherapeutic reagents. Cancer Biol Ther 2009; 8: 1651-1658.
15. Cao W, Zhang B, Liu Y, et al., High-level SLP-2 expression and HER-2/neu protein expression are associated with decreased breast cancer patient survival. Am J Clin Pathol 2007; 128: 430-436. (Pubitemid 47479976)
16. Chang D, Ma K, Gong M, et al., SLP-2 overexpression is associated with tumour distant metastasis and poor prognosis in pulmonary squamous cell carcinoma. Biomarkers 2010; 15: 104-110.
17. Dowling P, Meleady P, Dowd A, et al., Proteomic analysis of isolated membrane fractions from superinvasive cancer cells. Biochim Biophys Acta 2007; 1774: 93-101. (Pubitemid 46049136)
18. Li J, Zhang N, Song LB, et al., Astrocyte elevated gene-1 is a novel prognostic marker for breast cancer progression and overall patient survival. Clin Cancer Res 2008; 14: 3319-3326.
19. Rao JS,. Molecular mechanisms of glioma invasiveness: the role of proteases. Nature Rev Cancer 2003; 3: 489-501. (Pubitemid 37328837)
20. Kondraganti S, Mohanam S, Chintala SK, et al., Selective suppression of matrix metalloproteinase-9 in human glioblastoma cells by antisense gene transfer impairs glioblastoma cell invasion. Cancer Res 2000; 60: 6851-6855. (Pubitemid 32059151)
21. Gum R, Lengyel E, Juarez J, et al., Stimulation of 92-kDa gelatinase B promoter activity by ras is mitogen-activated protein kinase kinase 1-independent and requires multiple transcription factor binding sites including closely spaced PEA3/ets and AP-1 sequences. J Biol Chem 1996; 271: 10672-10680.
22. He C,. Molecular mechanism of transcriptional activation of human gelatinase B by proximal promoter. Cancer Lett 1996; 106: 185-191.
23. Hartmann C, Hentschel B, Wick W, et al., Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 2010; 120: 707-718.
24. Sanson M, Marie Y, Paris S, et al., Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 2009; 27: 4150-4154.
25. Yan H, Parsons DW, Jin G, et al., IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009; 360: 765-773.
26. Hegi ME, Diserens AC, Gorlia T, et al., MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352: 997-1003. (Pubitemid 40349502)
27. Esteller M, Garcia-Foncillas J, Andion E, et al., Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000; 343: 1350-1354.
28. Weller M, Stupp R, Reifenberger G, et al., MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nature Rev Neurol 2010; 6: 39-51.
29. Smith JS, Tachibana I, Passe SM, et al., PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 2001; 93: 1246-1256. (Pubitemid 32816199)
30. Jeuken J, Sijben A, Alenda C, et al., Robust detection of EGFR copy number changes and EGFR variant III: technical aspects and relevance for glioma diagnostics. Brain Pathol 2009; 19: 661-671.
31. Deryugina EI, Quigley JP,. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 2006; 25: 9-34. (Pubitemid 43723979)
32. Turpeenniemi-Hujanen T,. Gelatinases (MMP-2 and-9) and their natural inhibitors as prognostic indicators in solid cancers. Biochimie 2005; 87: 287-297. (Pubitemid 40387607)
33. Louis DN, Pomeroy SL, Cairncross JG,. Focus on central nervous system neoplasia. Cancer Cell 2002; 1: 125-128. (Pubitemid 41039158)
34. Chintala SK, Tonn JC, Rao JS,. Matrix metalloproteinases and their biological function in human gliomas. Int J Dev Neurosci 1999; 17: 495-502. (Pubitemid 29421836)
35. Chen LF, Greene WC,. Shaping the nuclear action of NF-kappaB. Nature Rev Mol Cell Biol 2004; 5: 392-401.
36. Naugler WE, Karin M,. NF-kappaB and cancer-identifying targets and mechanisms. Curr Opin Genet Dev 2008; 18: 19-26.
37. Perkins ND,. Integrating cell-signalling pathways with NF-kappaB and IKK function. Nature Rev Mol Cell Biol 2007; 8: 49-62. (Pubitemid 46012014)
38. Nakada M, Nakada S, Demuth T, et al., Molecular targets of glioma invasion. Cell Mol Life Sci 2007; 64: 458-478.
39. Tran NL, McDonough WS, Savitch BA, et al., The tumor necrosis factor-like weak inducer of apoptosis (TWEAK)-fibroblast growth factor-inducible 14 (Fn14) signaling system regulates glioma cell survival via NFkappaB pathway activation and BCL-XL/BCL-W expression. J Biol Chem 2005; 280: 3483-3492. (Pubitemid 40223813)